is a service-based partner for the pharmaceutical industry. We have a large number of PhD chemists, meaning we can offer over 25 years of experience to our customers from R&D pharmaceutical companies, biotech-companies, drug substance manufacturers and generic drug manufacturers.
is an investigational drug for acute decompensated heart failure under development by Debiopharm of Switzerland. It was originally identified and developed by sigma-tau Industrie Farmaceutiche Riunite SpA (sigma-tau) of Italy, from which Debiopharm acquired the right to develop and commercialise
Velcura Therapeutics announced the successful completion of a first-in-man clinical trial for its lead compound, VEL-0230, which the company is investigating as a treatment for Rheumatoid Arthritis and other bone diseases.
After 33 years and 500,000 customers, Dr. Siegal's® COOKIE DIET™ hunger-controlling foods will be available from non-medical retail franchises (PRWeb May 13, 2008) Read the full story at
The International Association of Whistleblowers, whose members include hundreds of qui tam relators and other whistleblowers from across the globe, announced that whistleblowers "Lawyer of the Year," Michael I. Behn of Chicago, Illinois, will deliver the keynote address to its
Thallion Pharmaceuticals has received authorization from the Therapeutic Products Directorate of Health Canada to begin a Phase II clinical trial evaluating TLN-4601 as a monotherapy treatment for patients with glioblastoma multiforme, an advanced form of brain cancer, as a second
Intercell and Iomai have entered into a definitive agreement pursuant to which Intercell will acquire Iomai for $6.60 per share representing a fully diluted equity value of approximately $189 million.
Warner Chilcott and Leo Pharma have announced that the FDA has approved the new drug application for Taclonex Scalp topical suspension for the treatment of moderate to severe psoriasis vulgaris of the scalp in adults.
Pipex Pharmaceuticals has received an orphan drug designation for oral tetrathiomolybdate from the FDA for the treatment of idiopathic pulmonary fibrosis.
Novadaq Technologies, a developer of real-time imaging and image guidance systems for use in the operating room, has announced that John Reidy, has been appointed CFO of the company, assuming the role on June 1, 2008.
Takeda Global R&D Center and Affymax have reported positive 12 month data from their ongoing Phase II trial evaluating the safety and tolerability of Hematide, an investigational drug in development for the treatment of anemia associated with chronic kidney disease.
Medarex has initiated the Phase II clinical development program of MDX-1100, a fully human monoclonal antibody that targets CXCL10, in ulcerative colitis and rheumatoid arthritis.
Proteome Sciences has reported that it has been selected to participate as a partner in the E13.7 million Sens-it-iv Framework 6 EU program, the largest integrated project in the EU funding program, the aim of which is to develop 'in-vitro'
Cardinal Health has completed the acquisition of assets of privately held Enturia, the manufacturer of infection prevention products sold under the ChloraPrep brand name.
Progenics Pharmaceuticals has reported a net loss of $15.5 million or $0.52 per share for the first quarter of 2008, compared to a net loss of $10.4 million or $0.40 per share for the first quarter of 2007.
The FDA has approved a new formulation of the genetically engineered version of Factor VIIa, a plasma protein essential for the clotting of blood. The new formulation allows the product to be stored at room temperature for up to two
ProStrakan Group has announced positive results from the pivotal US clinical program on Fortigel for testosterone replacement therapy in hypogonadal men. Based on these results, ProStrakan expects to re-file Fortigel with the FDA in the third quarter of 2008.
Affymax has reported a net loss of $15.6 million for the first quarter ended March 31, 2008 compared to a net loss of $7.2 million for the first quarter of 2007.
ABR-Affinity BioReagents, a global antibody manufacturer, has announced the finalization of new distribution agreements with LuBioScience, headquartered in Lucerne, Switzerland and Bio-Kasztel, located in Budapest, Hungary, further expanding its already extensive network of distribution partners in Europe.
